标题
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
作者
关键词
-
出版物
Nature Communications
Volume 8, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-08-29
DOI
10.1038/s41467-017-00450-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib
- (2015) P. N. Lara et al. CLINICAL CANCER RESEARCH
- Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models
- (2015) CLAIRE CRAFTER et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition
- (2015) Heiner Koch et al. JOURNAL OF PROTEOME RESEARCH
- Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
- (2015) Chee-Seng Tan et al. LANCET ONCOLOGY
- AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
- (2015) R. Ribas et al. MOLECULAR CANCER THERAPEUTICS
- Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
- (2015) E. M. Tricker et al. Cancer Discovery
- Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib
- (2015) Shengzhi Xie et al. Oncotarget
- BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
- (2015) Niki Karachaliou et al. Scientific Reports
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
- (2014) Ho-June Lee et al. CANCER CELL
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling
- (2014) Andrea Köhler et al. Molecular Cancer
- Inhibition of PI3K Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
- (2014) U. Hancox et al. MOLECULAR CANCER THERAPEUTICS
- Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway
- (2014) J J Havel et al. ONCOGENE
- Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
- (2014) Melissa Dumble et al. PLoS One
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of PI3K inhibitors: lessons learned from early clinical trials
- (2013) Jordi Rodon et al. Nature Reviews Clinical Oncology
- Role of PRAS40 in Akt and mTOR signaling in health and disease
- (2012) Claudia Wiza et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
- (2012) Ramaswamy Govindan et al. CELL
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
- (2012) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations
- (2011) R. Rosell et al. CLINICAL CANCER RESEARCH
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
- (2011) Trever G. Bivona et al. NATURE
- Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers
- (2011) H. W. Cheung et al. Cancer Discovery
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
- (2011) V. S. Rodrik-Outmezguine et al. Cancer Discovery
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers
- (2009) Guang Jin et al. LUNG CANCER
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
- (2009) A. C. Faber et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
- (2008) N. Rhodes et al. CANCER RESEARCH
- PIK3CA Mutations and Copy Number Gains in Human Lung Cancers
- (2008) H. Yamamoto et al. CANCER RESEARCH
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now